Catalyst Biosciences Alpha and Beta Analysis
| CBIODelisted Stock | USD 0.41 0.02 4.65% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Catalyst Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Catalyst Biosciences over a specified time horizon. Remember, high Catalyst Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Catalyst Biosciences' market risk premium analysis include:
Beta (1.16) | Alpha 1.1 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Catalyst |
Catalyst Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Catalyst Biosciences market risk premium is the additional return an investor will receive from holding Catalyst Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Catalyst Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Catalyst Biosciences' performance over market.| α | 1.10 | β | -1.16 |
Catalyst Biosciences Fundamentals Vs Peers
Comparing Catalyst Biosciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Catalyst Biosciences' direct or indirect competition across all of the common fundamentals between Catalyst Biosciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Catalyst Biosciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Catalyst Biosciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Catalyst Biosciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Catalyst Biosciences to competition |
| Fundamentals | Catalyst Biosciences | Peer Average |
| Return On Equity | -2.69 | -0.31 |
| Return On Asset | -0.38 | -0.14 |
| Current Valuation | 51.03 M | 16.62 B |
| Shares Outstanding | 37.97 M | 571.82 M |
| Shares Owned By Insiders | 27.73 % | 10.09 % |
| Shares Owned By Institutions | 8.75 % | 39.21 % |
| Number Of Shares Shorted | 34.05 K | 4.71 M |
Catalyst Biosciences Opportunities
Catalyst Biosciences Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | SCHWAZZE COMPLETES ACQUISITION TO MANAGE ASSETS OF NEW MEXICO CANNABIS OPERATOR, EVEREST APOTHECARY, INC. | 06/05/2023 |
2 | ABIVAX Socit Anonyme Announces Board Changes - Marketscreener.com | 07/11/2023 |
About Catalyst Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Catalyst or other delisted stocks. Alpha measures the amount that position in Catalyst Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Catalyst Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Catalyst Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Catalyst Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Catalyst Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Catalyst Biosciences. Please utilize our Beneish M Score to check the likelihood of Catalyst Biosciences' management manipulating its earnings.
| 13th of November 2023 Upcoming Quarterly Report | View | |
| 4th of April 2024 Next Financial Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of June 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Catalyst Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Catalyst Stock
If you are still planning to invest in Catalyst Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalyst Biosciences' history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |